ONCOZ — Oncozenge AB Share News
0.000.00%
Last trade - 00:00- SEK89.74m
- SEK96.49m
- SEK2.66m
Brief: OncoZenge: Final Outcome Of Rights Issue
Brief: OncoZenge: Preliminary Outcome Of Rights Issue
Brief: Oncozenge Files New Patent Application For Bupizenge
Brief: Oncozenge Makes Bupizenge Filings In 17 Markets
Brief: OncoZenge Says Investor Misses Payment Deadline For Remaining Fourth Tranche Shares
Brief: Oncozenge Secures Bridge Financing Of SEK 2.0 Mln
Brief: Oncozenge Q2 Net Sales Up At Sek 5 840
Brief: OncoZenge Resolves On Rights Issue Of About SEK 33.3 Mln
Brief: Oncozenge Extends Payment Deadline In Directed Share Issue
Brief: OncoZenge Extends Payment Deadline In Directed Share Issue
Brief: OncoZenge Extends Payment Deadline In Directed Share Issue
Brief: OncoZenge Extends Payment Deadline For Subscription Proceeds In Directed Issue
Brief: Oncozenge Resolves On Directed Share Issue To Strategic Investor
Brief: Oncozenge Receives Second Milestone Payment From Molteni Farmaceutici
Brief: Oncozenge Gets European Regulatory Approval To Start Pivotal Phase III Trial Of Bupizenge
Brief: Oncozenge Q1 2026 Net Sales Operating Loss SEK 6.8 Mln
Brief: Oncozenge Enters Into Loan Agreement Of SEK 2 Million With Linc
Brief: OncoZenge To Receive Decision On CTA By May 29
Brief: Oncozenge Receives Conditional Acceptance For Clinical Phase III Trial